First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study.

@article{Demetri2012FirstlineTO,
  title={First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study.},
  author={George Daniel Demetri and Axel le Cesne and Sant P. Chawla and Thomas Brodowicz and Robert G Maki and Bruce Allen Bach and Dominic P Smethurst and Sarah Bray and Yong-jiang Hei and J -Y Blay},
  journal={European journal of cancer},
  year={2012},
  volume={48 4},
  pages={547-63}
}
BACKGROUND Conatumumab is a fully human monoclonal agonist antibody that binds to death receptor 5 and induces apoptosis in sensitive cells. This study evaluated the safety and efficacy of doxorubicin ± conatumumab as first-line systemic therapy for metastatic or locally advanced/unresectable soft-tissue sarcoma. METHODS In Phase I, six patients received doxorubicin (75 mg/m2) with conatumumab (15 mg/kg) every 3 weeks. In Phase II, patients were randomised (2:1) to receive doxorubicin with… CONTINUE READING